Rett Syndrome: Tweaking One Gene Ingredient Raises Protein Levels 50-60%

Rett syndrome follows a particularly cruel developmental script. A girl is born, grows normally through her first months, and then - typically between six and eighteen months - begins to lose ground. Words disappear. Hand skills regress. Breathing becomes irregular. The condition, which affects roughly 1 in 10,000 girls, is caused by mutations in a single gene: MECP2. And for the 65% of patients whose mutations leave a partially functional version of the protein, a new study from Texas Children's Hospital and Baylor College of Medicine suggests a path that was not obvious before.

The gene as a recipe, and one optional ingredient

Understanding the approach requires a brief detour into gene structure. The MECP2 gene produces two slightly different protein variants - called E1 and E2 - depending on how the gene's segments, or exons, are spliced together. E1 is the dominant form in the brain. E2 is produced in smaller quantities and, crucially, is not associated with Rett syndrome: no patients have been reported with mutations specific to the E2 version.

The researchers, led by corresponding author Dr. Huda Zoghbi and first author Harini Tirumala, reasoned from that observation. If E2 is dispensable for normal brain function, and if E1 and E2 share the same genetic blueprint except for one exon (called e2), then guiding cells to skip that exon entirely should push more production toward E1 - potentially increasing E1 protein levels without adding entirely new genetic material.

"We also knew that there have been no reports of Rett syndrome patients carrying mutations on E2 protein. Only mutations that disrupt E1 protein cause the condition," Tirumala said. "This led us to hypothesize that guiding brain cells to skip the e2 ingredient would promote the production of more MeCP2-E1 protein in patients with Rett syndrome."

What happened in mice and patient cells

The team first deleted the e2 exon from normal mouse MECP2 and measured the effect. The result was a 50% to 60% increase in total MeCP2 protein - a substantial boost, and in the direction needed to compensate for the reduced levels caused by many Rett-causing mutations.

They then applied the same approach to cells derived from Rett syndrome patients - cells carrying MECP2 mutations that reduce both the protein's abundance and its activity. When the e2 exon was removed from the mutant gene, MeCP2 production increased. Depending on how severe the underlying mutation was, those cells recovered some or all of three key properties: normal cellular structure, normal electrical activity, and normal regulation of downstream genes.

"We were excited to see that deleting ingredient e2 enhanced MeCP2 production," Tirumala said. "Importantly, depending on the severity of the mutation, these cells recovered part or all of their normal structure, their normal electrical activity and their ability to regulate the levels of other genes."

From genetic deletion to potential drug

Permanently deleting DNA is not a clinically practical approach for most patients. The team therefore tested morpholinos - synthetic molecules that block access to the e2 exon during gene processing, effectively tricking cells into skipping it without altering the genome. In mice, morpholinos significantly increased MeCP2 protein levels.

Morpholinos themselves are too toxic for clinical use. But the principle they demonstrate is directly relevant to antisense oligonucleotides (ASOs) - a class of synthetic molecules already in clinical use for conditions including spinal muscular atrophy and Huntington's disease. ASOs work by a similar mechanism: they bind to RNA and alter how it is processed, without changing the underlying DNA.

"Although morpholinos themselves are not an option because of their toxicity, similar strategies, like antisense oligonucleotide therapies already used in other conditions, could potentially be developed for Rett syndrome," said Zoghbi, director of the Duncan Neurological Research Institute, Distinguished Service Professor at Baylor, and a Howard Hughes Medical Institute investigator.

A narrow target with a history of difficulty

MeCP2 is an unusually demanding therapeutic target. Too little of the protein causes Rett syndrome; too much causes a different neurological disorder, MECP2 Duplication Syndrome. Any therapy must increase protein levels within a precise range. The exon-skipping approach is appealing partly because it works with the gene's existing regulatory machinery rather than adding external protein - which might be harder to titrate precisely.

The study establishes proof of concept in mice and patient-derived cells. Significant work remains: demonstrating safety in animal models, developing a deliverable ASO formulation, and eventually moving to human trials. That process typically takes years. But for a condition with no approved cure and only one FDA-approved treatment for managing symptoms, a defined molecular target and a validated proof-of-concept mechanism is meaningful progress.